AstraZeneca (AZN) has released an update.
AstraZeneca’s Calquence, combined with chemoimmunotherapy, has shown a statistically significant improvement in progression-free survival for patients with mantle cell lymphoma. This marks the first time a BTK inhibitor has indicated a potential to extend overall survival compared to standard treatments. The findings will be discussed at an upcoming medical meeting and are part of AstraZeneca’s ongoing efforts to advance treatment in multiple B-cell blood cancers.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
